Zilucoplan Side Effects

Medically reviewed by Drugs.com. Last updated on Dec 10, 2024.

Applies to zilucoplan: parenteral injection for sub-q use.

Important warnings This medicine can cause some serious health issues

REMS:

FDA approved a REMS for zilucoplan to ensure that the benefits outweigh the risks.

The REMS may apply to one or more preparations of zilucoplan and consists of the following: elements to assure safe use and implementation system.

See the FDA REMS page ([Web]) for specific information.

Side effects include:

Most common adverse effects (≥10%): injection site reactions, upper respiratory tract infection, diarrhea.

For healthcare professionals

Applies to zilucoplan: subcutaneous solution.

General adverse events

The most common adverse effects in at least 10% of patients were injection site reactions, upper respiratory tract infections, and diarrhea.^[Ref]

Gastrointestinal

• Very common (10% or more): Diarrhea (11%)
• Common (1% to 10%): Nausea, vomiting
• Frequency not reported: Pancreatic events^[Ref]

Pancreatic events included pancreatitis and pancreatic cysts.^[Ref]

Genitourinary

• Common (1% to 10%): Urinary tract infection^[Ref]

Local

• Very common (10% or more): Injection site reactions (29%)

Other

• Common (1% to 10%): Increased lipase, increased amylase
• Frequency not reported: Meningococcal infection, transient elevations of blood eosinophils^[Ref]

Respiratory

• Very common (10% or more): Upper respiratory tract infections (14%)^[Ref]

Further information

Zilucoplan side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Note: Medication side effects may be underreported. If you are experiencing side effects that are not listed, submit a report to the FDA by following this guide.

Medical Disclaimer